Understanding whether your novel therapeutic can modulate or trigger phagocytosis could be key to the discovery phase of your immunotherapy drug. Phagocytosis is one of the main mechanisms of the innate immune response and the phagocytic cells most commonly involved are neutrophils, macrophages, monocytes and DCs.
At Aquila, we have a range of phagocytosis-based assays to help you understand the interaction between your compound or biologic and the phagocytic cells of the immune system, taking you to clinic faster.
Our phagocytosis assays, which can be tailored to your requirements, include:
- Clearance of dead or apoptotic cells (efferocytosis)
- Antibody-dependent cellular cytotoxicity (ADCP)
- Blocking of phagocytosis signals (e.g. CD47)
- Uptake of bacteria or yeast bioparticles
We work closely with you to select the most suitable approach based on the immune cells or disease of interest. Cargo for phagocytosis include bacteria, beads or tumour cells. Our standard readout uses the IncuCyte® Live-Cell Analysis System and customised readouts can include cytokine expression by ELISA, multiplex or MSD, proliferation and cell surface markers by multi-colour flow cytometry, or gene expression by qPCR or NGS.
Please get in touch to learn more about our phagocytosis assay services.